Nabriva Therapeutics, which is developing a novel antibiotic for bacterial pneumonia, filed on Thursday with the SEC to raise up to $92 million in an initial public offering.
The Vienna, Austria-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol NBRV. Nabriva Therapeutics initially filed confidentially on 5/14/2015. Leerink Partners and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
